Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 2, 2010, Pages 728-733

  Maïga, Almoustapha Issiaka ^a,e,g   Descamps, Diane ^b   Morand Joubert, Laurence ^c   Malet, Isabelle ^a   Derache, Anne ^a   Cisse, Mamadou ^d   Koita, Victoria ^d   Akonde, Alain ^e   Diarra, Bah ^f   Wirden, Marc ^a   Tounkara, Anatole ^g   Verlinden, Yvan ^h   Katlama, Christine ^a   Costagliola, Dominique ^a   Masquelier, Bernard ⁱ   Calvez, Vincent ^a   Marcelin, Anne Genevieve ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b BICHAT HOSPITAL   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d CESAC   (Mali)

^e Hôpital Nianankoro Fomba ^*  (Mali)

^f Hôpital Nianankoro Fomba   (Mali)

^g UNIVERSITY OF BAMAKO   (Mali)

^h Virco BVBA   (Belgium)

ⁱ BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; ETRAVIRINE; NEVIRAPINE;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; PHYLOGENY; PYRIDAZINES;

EID: 75749098448     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01335-09     Document Type: Article

References (26)

1. Andries, K., H. Azijn, T. Thielemans, D. Ludovici, M. Kukla, J. Heeres, P. Janssen, B. De Corte, J. Vingerhoets, R. Pauwels, and M. P. de Bethune. 2004. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48:4680-4686.
2. Balotta, C., G. Facchi, M. Violin, S. Van Dooren, A. Cozzi-Lepri, F. Forbici, A. Bertoli, C. Riva, D. Senese, P. Caramello, G. Carnevale, G. Rizzardini, L. Cremonini, L. Monno, G. Rezza, C. F. Perno, G. Ippolito, A. d'Arminio-Monforte, A. M. Vandamme, and M. Moroni. 2001. Increasing prevalence of non-clade B HIV-1 strains in heterosexual men and women, as monitored by analysis of reverse transcriptase and protease sequences. J. Acquir. Immune Defic. Syndr. 27:499-505.
3. Benhamida, J., C. Chappey, E. Coakley, and N. T. Parkin. 2008. XVII Int. HIV Drug Resist. Workshop, Sitges, Spain, 10 to 14 June 2008, abstr. 130.
4. Cotte, L., M. A. Trabaud, J. C. Tardy, C. Brochier, R. P. Gilibert, P. Miailhes, C. Trepo, and P. Andre. 2009. Prediction of the virological response to etravirine in clinical practice: comparison of three genotype algorithms. J. Med. Virol. 81:672-677.
5. Derache, A., A. I. Maiga, O. Traore, A. Akonde, M. Cisse, B. Jarrousse, V. Koita, B. Diarra, G. Carcelain, F. Barin, C. Pizzocolo, L. Pizarro, C. Katlama, V. Calvez, and A. G. Marcelin. 2008. Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006. J. Antimicrob. Chemother. 62:456-463.
6. Derache, A., O. Traore, V. Koita, A. Sylla, R. Tubiana, A. Simon, A. Canestri, G. Carcelain, C. Katlama, V. Calvez, M. Cisse, and A. G. Marcelin. 2007. Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, Mali. Antivir. Ther. 12:123-129.
7. Gazzard, B. G., A. L. Pozniak, W. Rosenbaum, G. P. Yeni, S. Staszewski, K. Arasteh, K. De Dier, M. Peeters, B. Woodfall, J. Stebbing, and G. A. vant' Klooster. 2003. An open-label assessment of TMC 125-a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS 17:F49-F54.
8. Geretti, A.-M. 2008. Shifting paradigms: the resistance profile of etravirine. J. Antimicrob. Chemother. 62:643-647.
9. Geretti, A. M., L. Harrison, H. Green, C. Sabin, T. Hill, E. Fearnhill, D. Pillay, and D. Dunn. 2009. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin. Infect. Dis. 48:1296-1305.
10. Gruzdev, B., A. Rakhmanova, E. Doubovskaya, A. Yakovlev, M. Peeters, A. Rinehart, K. de Dier, P. Baede-Van Dijk, W. Parys, and G. van 't Klooster. 2003. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. AIDS 17:2487-2494.
11. Holguin, A., E. Ramirez de Arellano, P. Rivas, and V. Soriano. 2006. Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes. AIDS Rev. 8:98-107.
12. Kagan, R. M., P. Sista, T. Pattery, L. Bacheler, and D. A. Schwab. 2009. Additional HIV-1 mutation patterns associated with reduced phenotypic susceptibility to etravirine in clinical samples. AIDS 23:1602-1605.
13. Kantor, R. 2006. Impact of HIV-1 pol diversity on drug resistance and its clinical implications. Curr. Opin. Infect. Dis. 19:594-606.
14. Kantor, R., D. A. Katzenstein, B. Efron, A. P. Carvalho, B. Wynhoven, P. Cane, J. Clarke, S. Sirivichayakul, M. A. Soares, J. Snoeck, C. Pillay, H. Rudich, R. Rodrigues, A. Holguin, K. Ariyoshi, M. B. Bouzas, P. Cahn, W. Sugiura, V. Soriano, L. F. Brigido, Z. Grossman, L. Morris, A. M. Vandamme, A. Tanuri, P. Phanuphak, J. N. Weber, D. Pillay, P. R. Harrigan, R. Camacho, J. M. Schapiro, and R. W. Shafer. 2005. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2:e112.
15. Lazzarin, A., T. Campbell, B. Clotet, M. Johnson, C. Katlama, A. Moll, W. Towner, B. Trottier, M. Peeters, J. Vingerhoets, G. de Smedt, B. Baeten, G. Beets, R. Sinha, and B. Woodfall. 2007. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370:39-48.
16. Llibre, J. M., J. R. Santos, T. Puig, J. Moltó, L. Ruiz, R. Paredes, and B. Clotet. 2008. Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz. J. Antimicrob. Chemother. 62:909-913.
17. Madruga, J. V., P. Cahn, B. Grinsztejn, R. Haubrich, J. Lalezari, A. Mills, G. Pialoux, T. Wilkin, M. Peeters, J. Vingerhoets, G. de Smedt, L. Leopold, R. Trefiglio, and B. Woodfall. 2007. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370:29-38.
18. Marcelin, A. G., P. Flandre, D. Descamps, L. Morand-Joubert, L. Charpentier, J. Izopet, M. A. Trabaud, T. Bourlet, B. Masquelier, and V. Calvez. 2009. 16th Conf. Retrovir. Oppor. Infect., Montreal, Canada, 9 to 11 February 2009, abstr. 645.
19. Perrin, L., L. Kaiser, and S. Yerly. 2003. Travel and the spread of HIV-1 genetic variants. Lancet Infect. Dis. 3:22-27.
20. Poveda, E., C. de Mendoza, T. Pattery, M. Gonzalez Mdel, J. Villacian, and V. Soriano. 2008. Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues. AIDS 22:2395-2398.
21. Robertson, D. L., J. P. Anderson, J. A. Bradac, J. K. Carr, B. Foley, R. K. Funkhouser, F. Gao, B. H. Hahn, M. L. Kalish, C. Kuiken, G. H. Learn, T. Leitner, F. McCutchan, S. Osmanov, M. Peeters, D. Pieniazek, M. Salminen, P. M. Sharp, S. Wolinsky, and B. Korber. 2000. HIV-1 nomenclature proposal. Science 288:55-56.
22. Tambuyzer, L., H. Azijn, L. T. Rimsky, J. Vingerhoets, P. Lecocq, G. Kraus, G. Picchio, and M. P. de Bethune. 2009. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors. Antivir. Ther. 14:103-109.
23. Vingerhoets, J., H. Azijn, E. Fransen, I. De Baere, L. Smeulders, D. Jochmans, K. Andries, R. Pauwels, and M. P. de Bethune. 2005. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J. Virol. 79:12773-12782.
24. Vingerhoets, J., H. Azijn, L. Tambuyzer, I. Dierynck, S. De Meyer, L. Rimsky, M. Peeters, G. De Smedt, M. P. De Bethune, and G. Picchio. 2008. 9th Int. Congr. Drug Ther. HIV Infect., Glasgow, United Kingdom, 9 to 13 November 2008, abstr. P189.
25. Vingerhoets, J., H. Azijn, L. Tambuyzer, A. Hoogstoel, S. Nijs, M. P. De Bethune, and G. Picchio. 2008. XVII Int. HIV Drug Resist. Workshop, Sitges, Spain, 10 to 14 June 2008, abstr. 24.
26. Winters, B., J. Villacian, E. Van Craenenbroeck, and L. Bacheler. 2008. 15th Conf. Retrovir. Oppor. Infect., Boston, MA, 3 to 8 February 2008, abstr. 873.